FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2470301550> ?p ?o ?g. }

• W2470301550 abstract "Background and aim - The development of clinical manifectations due to an eroded or ruptured atherosclerotic plaque, or occluded vessel, are one of the major causes of death world wide. It has been known for some time that atherosclerosis develops due to retention and modification of LDL particles in the vessel wall and the subsequent triggering of the immune system. The research presented within this thesis has focused on IL-16, a signaling molecule, in the immune system.. IL-16 has shown pleiotropic functions in inflammatory diseases. IL-16 has been described to have the capacity to induce T cell unresponsivness and increase the regulatory T cell population. Regulatory T cells are known to be protective in atherosclerosis by dampening the immune responses. There has been no extensive research on the role of IL-16 in atherosclerosis disease and the clinical manifestations thereof. The aim of the collected work in this thesis was to investigate if IL-16 can induce anti-inflammatory and atherosclerosis dampening effects, if IL-16 holds potential as a biomarker for predicting future cardiovascular events, and if IL-16 is altered in an retrospective cardiovascular case-control study.Results – (I) Administration of IL-16, in an experimental model of atherosclerosis consisting of hypercholesterolemic female mice, increased anti-inflammatory factors and decreased the atherosclerotic plaque burden. Male mice, which were defective of IL-16, displayed an increased atherosclerotic burden compared to control mice. (II) Elevated levels of IL-16, in carotid plaques, from individuals with severe carotid atherosclerosis displayed associations to plaque stabilizing components (collagen, elastin and FoxP3). High levels of carotid plaque IL-16 were associated to a decreased risk of suffering from a cardiovascular event. (III) Individuals suffering from severe carotid atherosclerosis had a decreased risk of suffering from a post-operative cardiovascular event, or a cardiovascular event leading to death, if they had high levels of circulating IL-16 compared to individuals with low levels of IL-16. (IV) In a population-based prospective study four single nucleotide polymophisms (SNPs) were found to be associated with IL-16 plasma levels. High plasma levels of IL-16 were associated with an increased risk of myocardial infarction in women, compared to women with low levels of circulating IL-16. None of the SNPs were associated with an increased risk of cardiovascular events. One of the identified SNPs was associated with a decreased risk of all-cause mortality during the 20-year follow-up period. (V) In a retrospective case-control study, including individuals suffering from diabetes, IL-16 was 50% elevated in individuals whom also suffered from cardiovascular complications compared to the individuals only suffering from diabetes. Plasma levels of IL-16 were associated with surrogate markers of atherosclerosis which was further supported by SNP analysis.Conclusion - IL-16 in plasma did not display associations to a decreased risk of cardiovascular events in a prospective population-based study, rather the opposite. We have presented supporting evidence of a protective role of IL-16 in severe and experimental atherosclerosis, reinforced by the associations between high IL-16 levels and increasing amounts of stabilizing factors in the atherosclerotic plaque. We also present supporting evidence, in an experimental setting, for an anti-inflammatory role and plaque burden limiting role of IL-16. The data presented within this thesis warrants further investigation of the plaque stabilizing properties of IL-16 in severe atherosclerosis and the role of IL-16 in promoting anti-inflammatory mediators." @default.
• W2470301550 created "2016-07-22" @default.
• W2470301550 creator A5042106680 @default.
• W2470301550 date "2016-01-01" @default.
• W2470301550 modified "2023-09-26" @default.
• W2470301550 title "Interleukin 16 in Atherosclerosis and Cardiovascular Disease" @default.
• W2470301550 cites W130007289 @default.
• W2470301550 cites W1485021502 @default.
• W2470301550 cites W1493736027 @default.
• W2470301550 cites W1494340137 @default.
• W2470301550 cites W1507160172 @default.
• W2470301550 cites W1509514214 @default.
• W2470301550 cites W1513554303 @default.
• W2470301550 cites W1520336076 @default.
• W2470301550 cites W1522377278 @default.
• W2470301550 cites W1602100985 @default.
• W2470301550 cites W1607492210 @default.
• W2470301550 cites W1748311474 @default.
• W2470301550 cites W1776759521 @default.
• W2470301550 cites W1929235053 @default.
• W2470301550 cites W1949604988 @default.
• W2470301550 cites W1964064254 @default.
• W2470301550 cites W1966248894 @default.
• W2470301550 cites W1968171440 @default.
• W2470301550 cites W1968350849 @default.
• W2470301550 cites W1975750642 @default.
• W2470301550 cites W1976622358 @default.
• W2470301550 cites W1977649824 @default.
• W2470301550 cites W1979358608 @default.
• W2470301550 cites W1979938844 @default.
• W2470301550 cites W1982283178 @default.
• W2470301550 cites W1985999456 @default.
• W2470301550 cites W1986868330 @default.
• W2470301550 cites W1987088928 @default.
• W2470301550 cites W1989583350 @default.
• W2470301550 cites W1994589849 @default.
• W2470301550 cites W1995808454 @default.
• W2470301550 cites W1997351055 @default.
• W2470301550 cites W1997443963 @default.
• W2470301550 cites W1997507987 @default.
• W2470301550 cites W2000155500 @default.
• W2470301550 cites W2001467511 @default.
• W2470301550 cites W2008960002 @default.
• W2470301550 cites W2011587009 @default.
• W2470301550 cites W2012690683 @default.
• W2470301550 cites W2012771346 @default.
• W2470301550 cites W2012855718 @default.
• W2470301550 cites W2013556191 @default.
• W2470301550 cites W2015879727 @default.
• W2470301550 cites W2016454174 @default.
• W2470301550 cites W2016642932 @default.
• W2470301550 cites W2020713861 @default.
• W2470301550 cites W2020784818 @default.
• W2470301550 cites W2021538881 @default.
• W2470301550 cites W2027516092 @default.
• W2470301550 cites W2030452278 @default.
• W2470301550 cites W2032207767 @default.
• W2470301550 cites W2033002648 @default.
• W2470301550 cites W2034929991 @default.
• W2470301550 cites W2035848833 @default.
• W2470301550 cites W2036523089 @default.
• W2470301550 cites W2037829967 @default.
• W2470301550 cites W2040207960 @default.
• W2470301550 cites W2042546636 @default.
• W2470301550 cites W2044757050 @default.
• W2470301550 cites W2045887180 @default.
• W2470301550 cites W2046016065 @default.
• W2470301550 cites W2048659881 @default.
• W2470301550 cites W20509213 @default.
• W2470301550 cites W2050997693 @default.
• W2470301550 cites W2051055532 @default.
• W2470301550 cites W2058158581 @default.
• W2470301550 cites W2059638443 @default.
• W2470301550 cites W2060034277 @default.
• W2470301550 cites W2065726023 @default.
• W2470301550 cites W2066571367 @default.
• W2470301550 cites W2068700927 @default.
• W2470301550 cites W2070850641 @default.
• W2470301550 cites W2071041688 @default.
• W2470301550 cites W2072681095 @default.
• W2470301550 cites W2073751205 @default.
• W2470301550 cites W2077640549 @default.
• W2470301550 cites W2081343055 @default.
• W2470301550 cites W2081527966 @default.
• W2470301550 cites W2083154566 @default.
• W2470301550 cites W2083384274 @default.
• W2470301550 cites W2083709056 @default.
• W2470301550 cites W2084052630 @default.
• W2470301550 cites W2084341751 @default.
• W2470301550 cites W2085087376 @default.
• W2470301550 cites W2086766576 @default.
• W2470301550 cites W2087472697 @default.
• W2470301550 cites W2090937916 @default.
• W2470301550 cites W2091173515 @default.
• W2470301550 cites W2092834104 @default.
• W2470301550 cites W2094768566 @default.
• W2470301550 cites W2098537370 @default.
• W2470301550 cites W2099796320 @default.
• W2470301550 cites W2100963925 @default.
• W2470301550 cites W2101844022 @default.

• next